

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 09, 2026**

---

**FibroBiologics, Inc.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-41934**  
(Commission File Number)

**86-3329066**  
(IRS Employer  
Identification No.)

**9350 Kirby Drive, Suite 300**  
**Houston, Texas**  
(Address of Principal Executive Offices)

**77054**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 281 671-5150**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00001 par value	FBLG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 7.01 Regulation FD Disclosure.**

On April 20, 2026, FibroBiologics, Inc. (the “Company”) issued a press release announcing formal confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market and, accordingly, the previously disclosed listing matter has been closed. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

**Item 8.01 Other Events.**

On April 17, 2026, the Company received formal notice from Nasdaq that the Company has demonstrated compliance with the bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previously disclosed listing matter has been closed.

The Company was also informed that it will remain subject to a Mandatory Panel Monitor for a period of one year from April 17, 2026. If within that one-year monitoring period the Company fails to maintain compliance with the Bid Price Rule, the Company will not be afforded a cure period to regain compliance with the Bid Price Rule. Instead, Staff will issue a delist determination, at which time the Company may request a new hearing before a Nasdaq Hearings Panel. Such request would stay any further delisting action by Nasdaq at least pending the conclusion of the hearing process.

Previously, on March 9, 2026, the Company received notice from Nasdaq that the Company had demonstrated compliance with the stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) in lieu of compliance with the alternative market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). The compliance determination also noted that the Company remained subject to a Mandatory Panel Monitor with respect to the Equity Rule for a period of one year from March 9, 2026. If within that one-year monitoring period the Company fails to satisfy the Equity Rule, the Company will not be permitted to provide the Nasdaq Listing Qualifications Staff with a compliance plan nor would the Staff be permitted to grant additional time to the Company to regain compliance. Instead, the Staff will issue a delist determination, at which time the Company may request a new hearing before a Nasdaq Hearings Panel. Such request would stay any delisting action by Nasdaq at least pending the conclusion of the hearing process.

**Item 9.01 Financial Statements and Exhibits.**

Exhibit 99.1	Press Release dated April 20, 2026
Exhibit 104	Cover Page Interactive Data File (embedded within the inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FibroBiologics, Inc.

Date: April 20, 2026

By: /s/ Pete O'Heeron

Name: Pete O'Heeron

Titel: Chief Financial Officer

---

**FibroBiologics Compliant with All Nasdaq Listing Requirements**

HOUSTON, April 20, 2026 -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has confirmed that the Company has demonstrated compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the \$2.5 million stockholders' equity requirement and the \$1.00 bid price requirement.

The Company has now successfully resolved its Nasdaq compliance issues but will remain subject to one-year monitoring periods for both stockholders' equity and bid price compliance. FibroBiologics' common stock will continue to be listed and trade on Nasdaq under the symbol "FBLG."

For more information, please visit FibroBiologics' website, email FibroBiologics at [info@fibrobiologics.com](mailto:info@fibrobiologics.com) or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

**Cautionary Statement Regarding Forward-Looking Statements**

This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company's intent or ability to maintain compliance with the applicable Nasdaq continued listing rules and the continued listing and trading of the Company's shares of common stock on Nasdaq. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, [www.sec.gov](http://www.sec.gov). These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) FibroBiologics' ability to manufacture its product candidates; and (e) FibroBiologics' ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to

---

update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

**About FibroBiologics**

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit [www.FibroBiologics.com](http://www.FibroBiologics.com).

**General Inquiries:**

[info@fibrobiologics.com](mailto:info@fibrobiologics.com)

**Investor Relations:**

Nic Johnson  
Russo Partners  
(212) 845-4242  
[fibrobiologicsIR@russopr.com](mailto:fibrobiologicsIR@russopr.com)

**Media Contact:**

Liz Phillips  
Russo Partners  
(347) 956-7697  
[Elizabeth.phillips@russopartnersllc.com](mailto:Elizabeth.phillips@russopartnersllc.com)

---